Sequencing Considerations in mCRPC

 

Stanford Medicine
J

Stanford Medicine Historical Landscape of Testing: Blood-Based Diagnostic Biomarkers & Screening

By Stanford Medicine FEATURING John Leppert
By Stanford Medicine FEATURING John Leppert
29 views
July 9, 2022
0 Comments
Login to view comments. Click here to Login
Sequencing Considerations in mCRPC
51
Dana-Farber Cancer Institute

Lecture Summary - CARD Trial: Safety and Efficacy of Cabazitaxel in …

Feat. A. Choudhury
09:06
Dana-Farber Cancer Institute

CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Su…

Feat. A. Choudhury
08:33
Penn Medicine Abramson Cancer Center

Challenging Genitourinary Tumors: What’s New in Prostate Cancer

Feat. V. Narayan
22:50
Stanford Medicine

Genetics/Genomics in Prostate Cancer

Feat. M. Cooperberg
23:27
Stanford Medicine

Stanford Medicine Historical Landscape of Testing: Blood-Based Diagn…

Feat. J. Leppert
38:10
Nebraska Oncology Society

ASCO 2022 Updates on Molecular Based Imaging for Prostate Cancer: Re…

Feat. T. Hope
21:43
ecancer

ASCO 2022 on the Latest Developments in mHSPC and mCRPC

Feat. H. Payne, K. Chi, K. Miller, L. Krabbe
44:50
Masonic Cancer Center, University of Minnesota

New Therapeutic Discoveries and Mechanisms for CRPC

Feat. K. Kelly
14:33
Martin Allen-Auerbach

Prostate Cancer Imaging Updates: What, Why, and When

06:00
Elena Castro

Cabazitaxel Activity in Men With mCRPC With & Without DNA Damage…

10:02
Eleni Efstathiou

The Role of Biomarkers in mCRPC

13:49
Benjamin L. Maughan

Finding the Optimal Sequence for mCRPC

07:31
Karam Al-Issa

Second Line Therapy Options in mCRPC

06:12
Giulia Baciarello

Patient Preference Between Cabazitaxel and Docetaxel for 1L Chemothe…